Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases (CAPLocal) : A Multicentre, Single-Arm,Prospective Cohort Study

NCT07482670 is registered in ClinicalTrials.gov with Xiangya Hospital of Central South University as lead sponsor.

NCT NCT07482670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07482670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases (CAPLocal) : A Multicentre, Single-Arm,Prospective Cohort Study
Lead sponsor
Xiangya Hospital of Central South University
Phase
Observational
Overall status
Not yet recruiting
Start date
March 2, 2026
Completion date
December 31, 2028
Enrollment
32 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatecellular carcinoma